Prostagerb N - instructions for use, doses, side effects, contraindications

Active substanceStinging nettle extractsStinging nettle extracts

Similar drugsTo uncover

Prostagerbe® H

pills inwards

Cesra Artsnimittel GmbH & Co. KG. KG

Dosage form: & nbsp

coated tablets

Composition:

One coated tablet contains: Nettle roots extract - 230 mg, standardized consisting of:

Active Ingredient:

nettle roots extract native dry (7.1 - 14.3: 1) - 161.0 mg

Excipient: lactose - 69.0 mg

Excipients: cellulose microcrystalline - 28.0 mg, polyvidone - 6,0 mg, crospovidone - 4.0 mg, talc - 3.3 mg, silicon dioxide colloid - 2.4 mg, magnesium stearate - 1.3 mg;

Shell composition: a copolymer of methacrylic acid, type A - 1.62 mg; dibutyl phthalate 0.16 mg, magnesium carbonate 8.61 mg, talc 36.65 mg gum arabicum 6.47 mg titanium dioxide (E 171) 13.26 mg glucose syrup (based on dry matter ) - 3.4 mg, macrogol 6000 - 6.79 mg, polyvidon 0.97 mg, calcium carbonate (E 170) 19.4 mg, sucrose 124.32 mg, opalux AS 26520 - 2.38 mg, calol 600 Pharma - 0.5 mg.

Description:

Biconvex, round tablets, coated with a shell, brown; on the fracture - a brown core and a two-layer shell (the inner layer is white, the outer one is brown).

Pharmacotherapeutic group:Prostate hyperplasia is a benign treatment of plant origin.

ATX: & nbsp

G.04.B.X Other drugs for the treatment of urological diseases

Pharmacodynamics:

Normalizes diuresis with a benign enlargement of the prostate gland: it increases the volume and maximum outflow of urine and reduces the amount of residual urine, reduces dysuria, nocturia, pain. Does not affect the volume of the enlarged prostate.

Pharmacokinetics:No data available.

Indications:

Complex therapy of disorders of urination with benign prostatic hyperplasia of the I and II stages.

Contraindications:

Increased individual sensitivity to the drug components, chronic heart and kidney failure, lactose intolerance, fructose intolerance, lactase deficiency, sugar / isomaltase deficiency, glucose-galactose malabsorption, children's age (under 18 years).

Carefully:not described

Pregnancy and lactation:

Not applicable. This drug is not intended for use in women.

Dosing and Administration:

Inside for 1 tablet, covered with a shell, 3 times a day. The tablet should be taken, not chewing and washing down with a little water. The course of treatment is from 2 to 6 months. The duration of the course of treatment is determined by the doctor.

Side effects:

There may be mild reactions from the gastrointestinal tract (nausea, heartburn, a feeling of overflow, diarrhea, flatulence), allergic reactions (itching, skin rash, including urticaria) that occur after the drug is discontinued.

Overdose:

To date, cases of overdose have not been described.

Interaction:Not identified.

Special instructions:

If you take the drug y. You will develop side effects that are not listed in this manual, you should immediately contact your doctor.

When blood appears in the urine or acute urinary retention, you should consult your doctor.

Patients with diabetes should take into account that 1 tablet contains 0.2 g of carbohydrates, which corresponds to 0.02 XE.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

The tablets covered with a cover.

For 20 tablets in a blister of PVC / aluminum foil. For 3, 6 or 10 blisters in a cardboard box together with instructions for use.

Packaging:packs cardboard

Storage conditions:

At a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:П N010251

Date of registration:30.06.2006

The owner of the registration certificate:Cesra Artsnimittel GmbH & Co. KG. KGCesra Artsnimittel GmbH & Co. KG. KG

Manufacturer: & nbsp

Cesra Artsnimittel GmbH & Co. KG. KG Germany

Representation: & nbspAlpen Pharma, Open CompanyAlpen Pharma, Open Company

Information update date: & nbsp26.03.2015

Illustrated instructions

Instructions

Prostagerbe® H (Prostaherb® N)